STOCK TITAN
  1. Home
  2. Sec-filings
  3. MANE
  4. [8-K] Veradermics, Inc Reports Material Event

Veradermics (NYSE: MANE) reports $390.8M preliminary cash and securities

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Veradermics, Incorporated reports a preliminary unaudited balance of cash, cash equivalents and marketable securities of about $390.8 million as of March 31, 2026.

The figure was prepared by management and is subject to the company’s normal financial closing procedures, so the final amount in the unaudited condensed consolidated financial statements for the three months ended March 31, 2026 may differ materially. The company notes that Deloitte & Touche LLP has not audited, reviewed, examined, compiled or applied agreed-upon procedures to this preliminary data and therefore does not provide any assurance on it.

Positive

  • None.

Negative

  • None.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Cash, cash equivalents and marketable securities $390.8 million Preliminary unaudited balance as of March 31, 2026
preliminary unaudited financial
"had a preliminary unaudited amount of cash, cash equivalents and marketable securities"
Preliminary unaudited means reported financial figures are an early, draft version that have not yet been checked and signed off by an independent auditor. Think of it like a first draft of a school report: it gives a useful snapshot of performance but may contain errors or adjustments before it becomes final. Investors care because numbers can change after review, so preliminary unaudited results carry more uncertainty when valuing a company or making trading decisions.
marketable securities financial
"cash, cash equivalents and marketable securities of approximately $390.8 million"
Marketable securities are financial assets — such as publicly traded stocks, bonds, and short-term government bills — that a company can quickly sell for cash at a known price. Investors watch them because they show how much ready cash a company can access without selling core operations, like keeping money in a highly liquid savings account versus being tied up in a house, and they affect short-term risk, financial flexibility, and balance-sheet strength.
financial closing procedures financial
"subject to completion of the Company’s financial closing procedures"
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
agreed-upon procedures financial
"nor applied agreed-upon procedures with respect to the preliminary financial data"
Cash, cash equivalents and marketable securities $390.8 million
Understanding 8-K Material Events →
0001827635False00018276352026-04-272026-04-27

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 27, 2026
VERADERMICS, INCORPORATED
(Exact name of registrant as specified in its charter)
Delaware001-4309784-3304423
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
470 James Street
New Haven, CT
06513
(Address of principal executive offices)(Zip Code)
(Registrant’s telephone number, including area code): (228) 372-3376
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common Stock, par value $0.00001 per shareMANENew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 2.02 Results of Operations and Financial Condition.

Veradermics, Incorporated (the “Company”) reports that it had a preliminary unaudited amount of cash, cash equivalents and marketable securities of approximately $390.8 million as of March 31, 2026. This amount is preliminary and unaudited and is subject to completion of the Company’s financial closing procedures. As a result, this amount may differ materially from the amount that will be reflected in the Company’s unaudited condensed consolidated financial statements for the three months ended March 31, 2026. This preliminary unaudited financial data has been prepared by, and is the responsibility of, the Company’s management. Deloitte & Touche LLP, the Company’s auditor, has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, Deloitte & Touche LLP does not express an opinion or any other form of assurance with respect thereto.


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
VERADERMICS, INCORPORATED
By:/s/ Reid Waldman, M.D.
Name: Reid Waldman, M.D.
Chief Executive Officer
Date: April 27, 2026

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents